Could the GLP-1 boom deepen health inequities?

Clinical takeaway: Prescribe GLP-1 therapies within a broader obesity-management strategy that also addresses social determinants of health, food environments, and equitable access, as growing commercial pressures may undermine public health goals.

GLP-1 receptor agonists have rapidly transformed obesity care and prompted the World Health Organization's first global guideline recommending these medications for obesity treatment. At the same time, WHO is emphasizing both fair access to GLP-1s and policy reforms targeting unhealthy food environments, raising questions about how commercial interests could shape the next phase of obesity care.

In a Science editorial, authors argue that the expanding "Ozempic era" is creating powerful incentives for pharmaceutical, wellness, and food companies that may conflict with efforts to improve population health and reduce obesity-related inequities. The authors note that obesity affects roughly 1 billion people worldwide, making GLP-1 therapies one of the largest emerging markets in health care.

The editorial highlights concerns that industry stakeholders are increasingly framing obesity as a chronic disease requiring long-term medical treatment, potentially shifting attention away from prevention and broader food-system reforms. The authors also point to the growth of telemedicine weight-management programs, direct-to-consumer services, and same-day medication delivery models that may remain financially out of reach for many patients.

High prices for branded GLP-1 drugs, they argue, could widen disparities in access while fueling demand for unapproved compounded or generic products and other potentially unsafe weight-loss alternatives. At the same time, food manufacturers may respond to declining demand for ultraprocessed foods by marketing "GLP-1 lifestyle" products, reformulating foods, or otherwise adapting their offerings in ways that preserve profits without addressing underlying drivers of obesity.

According to the authors, the combination of equitable access policies and food-environment reforms remains the most promising path forward. As they conclude: "To ensure that GLP-1s reduce rather than deepen health inequities, governments and health care leaders must erect guardrails for commercial forces jumping on the GLP-1 bandwagon."

Source: Hagenaars LL, Schmidt LA. (2026 Sep 3) Science. (Un)intended Consequences of Mass-Prescribing GLP-1s